The landscape of newborn screening (NBS) is changing as new tools are developed. We must acknowledge that NBS is a very important and extraordinarily positive initiative especially for rare and serious inherited disorders; however, lessons learned from current NBS should guide the future of NBS as we enter the era of “omics” that will expand NBS for many other genetic disorders. In this article, I will first discuss new tools such as genomics and metabolomics for NBS. I will then turn to assessing how best to take advantage of new technical developments while considering the best interests of patients and the success of newborn screening.
CITATION STYLE
Ficicioglu, C. (2017). New tools and approaches to newborn screening: ready to open Pandora’s box? Molecular Case Studies, 3(3), a001842. https://doi.org/10.1101/mcs.a001842
Mendeley helps you to discover research relevant for your work.